Marksans Pharma Q2 Results Preview: Margin Trend, Base Quarter and Valuation

CMP Rs 335.50. Jun26 revenue Rs 841 Cr, net profit Rs 159 Cr, OPM 25.33%. PE 29.36x, ROE 15.2%. Q2 FY27 date not yet announced.

Marksans Pharma Q2 results are on the radar of pharma investors heading into the October to November reporting window, especially after a run of five straight quarters of margin expansion for the generics maker. Track the latest Marksans Pharma Ltd. share price on Univest as the Marksans Pharma Q2 results season approaches, and read this Marksans Pharma Q2 results preview for the historical numbers behind the story.

Marksans Pharma Q2 Results Date

The Marksans Pharma Q2 results date for the quarter ended September 30, 2026 has not been announced. Companies across the Indian pharma sector typically report Q2 FY27 numbers in October or November, and Marksans Pharma Q2 results have historically followed a similar cadence. No confirmed Marksans Pharma Q2 results date is available at the time of writing, so investors should track the company’s BSE and NSE filings directly for the board meeting intimation rather than relying on unverified dates for Marksans Pharma Q2 results 2026.

Marksans Pharma Q2 Results Expectations

Marksans Pharma Q2 Results Expectations should be framed around the margin and profit trend visible in the data, not a specific numeric forecast, since no verified analyst estimate exists for the September quarter. Operating margin for Marksans Pharma has expanded in every single quarter of the available data, from 16.13% in Jun25 to 25.33% in Jun26, a run that gives useful context for Marksans Pharma Q2 results expectations without predicting a number. Revenue has grown from Rs 620 Cr in Jun25 to Rs 841 Cr in Jun26, and net profit has nearly tripled from Rs 58 Cr to Rs 159 Cr across the same five quarters, a trend line that frames how the market is likely to read the next Marksans Pharma Q2 results. The screener note on this stock flags consistent margin expansion with no one-off items across the period, which is a useful qualifying detail while building Marksans Pharma Q2 results expectations for FY27.

Also read – Dabur India Q2 Results FY27 Preview

Previous Quarter: Q1 FY27 (Jun26) Performance

In the previous quarter, Jun26 or Q1 FY27, Marksans Pharma reported revenue of Rs 841 Cr, operating profit of Rs 213 Cr, an operating margin of 25.33%, and net profit of Rs 159 Cr. This was the highest operating margin recorded in the five-quarter data set, even though revenue eased marginally from the Rs 856 Cr posted in Mar26. Net profit of Rs 159 Cr in Jun26 was also the highest in the series, ahead of the Rs 149 Cr reported in Mar26, which sets a strong sequential bar for the upcoming Marksans Pharma Q2 results.

Base Quarter: Q2 FY26 (Sep25) Performance

The year ago quarter for Marksans Pharma Q2 results is Sep25, or Q2 FY26, when the company reported revenue of Rs 720 Cr, operating profit of Rs 144 Cr, an operating margin of 20.0%, and net profit of Rs 99 Cr. This Sep25 base is the quarter against which the eventual September 2026 Marksans Pharma Q2 results will be measured on a year on year basis. With Jun26 revenue already at Rs 841 Cr and net profit at Rs 159 Cr, both comfortably ahead of the Sep25 base, the year on year comparison embedded in the next Marksans Pharma Q2 results starts from a stronger prior-year reference point.

Recent Trend: Jun25 to Jun26

The five-quarter run from Jun25 through Jun26 is the clearest evidence available for framing Marksans Pharma Q2 results. Revenue rose steadily from Rs 620 Cr (Jun25) to Rs 720 Cr (Sep25) to Rs 754 Cr (Dec25) to Rs 856 Cr (Mar26) to Rs 841 Cr (Jun26). Operating margin expanded in each period without exception, moving from 16.13% to 20.0% to 21.35% to 22.78% and finally to 25.33%. Net profit followed the same upward arc, from Rs 58 Cr in Jun25 to Rs 159 Cr in Jun26, roughly a 174% increase over five quarters. This consistent, uninterrupted trend of margin expansion is the single biggest talking point around Marksans Pharma Q2 results as the market waits for the September quarter print, since no one-off items have been flagged across the entire stretch.

Key Factors to Watch in Marksans Pharma Q2 Results

Several factors are worth watching ahead of Marksans Pharma Q2 results. First, whether the operating margin can extend past the 25.33% high recorded in Jun26, or whether it consolidates near current levels, will be a central talking point once Marksans Pharma Q2 results are announced. Second, revenue growth momentum, which has averaged a steady upward slope over five quarters with only a marginal Jun26 dip from the Mar26 peak, is relevant context for how Marksans Pharma Q2 results might shape up. Third, the pharma and generics business is sensitive to US formulation approvals, currency movements and input costs, all of which sit outside the scope of the historical data provided here but remain relevant background for Marksans Pharma Q2 results. None of these points should be read as a forecast, they are simply the observable drivers behind the reported numbers so far.

Valuation Ahead of Marksans Pharma Q2 Results

On valuation, Marksans Pharma trades at a CMP of Rs 335.50, close to its 52 week high of Rs 349.95 and well above its 52 week low of Rs 155.0. The stock’s trailing PE is 29.36x on an EPS of Rs 11.43, with a price to book ratio of 5.03x against a book value of Rs 66.7. Return on equity stands at 15.2%, debt to equity is low at 0.11x, and the dividend yield is 0.28%. Market capitalisation is around Rs 15,187 crore. The 50 day moving average of Rs 300.95 and the 200 day moving average of Rs 223.53 both sit below the CMP, and the RSI of 51.69 indicates a neutral technical setup as the market awaits Marksans Pharma Q2 results.

Also read – Dalmia Bharat Q2 Results FY27 Preview

What to Watch in Marksans Pharma Q2 Results FY27

Heading into Marksans Pharma Q2 results for FY27, the key data points to track once numbers are out are whether revenue growth continues its five-quarter climb, whether the operating margin holds above the 25% mark it touched in Jun26, and how net profit compares with both the Rs 159 Cr Jun26 base and the Rs 99 Cr Sep25 year ago quarter. The formal announcement of a Marksans Pharma Q2 results date on the exchanges is also worth watching, since none has been confirmed as of this writing. Any post-results commentary from management would add color that the historical financial data alone cannot provide.

Conclusion

Marksans Pharma Q2 results for the September 2026 quarter arrive on the back of five consecutive quarters of margin expansion and steady profit growth, a track record that sets a demanding bar for the upcoming print. With a market capitalisation of Rs 15,187 crore and a PE of 29.36x, the stock is priced for continuity of that trend, which makes the eventual Marksans Pharma Q2 results an important checkpoint for the pharma sector’s earnings season this year.

Following pharma stocks through every reporting cycle? Open a free Univest demat account and build a watchlist that tracks names like this one.

Get set up before results season peaks. Start investing with Univest and access research tools for the Indian markets.

Want quarterly updates on generics and pharma exporters? Create your free Univest demat account and stay on top of every earnings cycle.

Univest is a SEBI registered Research Analyst, Registration No. INH000013776. This article is prepared for informational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security. All historical financial figures for Marksans Pharma Ltd. cited above are sourced from publicly available company disclosures and are subject to revision. The Q2 FY27 results date and figures have not been announced and no forecast is implied. Please consult your own financial advisor and review official exchange filings before making any investment decision. Investments in securities are subject to market risk, read all related documents carefully.

When will Marksans Pharma Q2 results be announced?

Ans. The Marksans Pharma Q2 results date for the quarter ended September 30, 2026 has not been announced yet. Companies typically announce Q2 results in the October to November window.

What are the expectations from Marksans Pharma Q2 results?

Ans. Marksans Pharma Q2 Results Expectations are framed around the trend, since operating margin has expanded in every quarter of available data, from 16.13% in Jun25 to 25.33% in Jun26, with no numeric forecast possible.

How did Marksans Pharma perform in the previous quarter (Q1 FY27)?

Ans. In the previous quarter, Jun26 (Q1 FY27), Marksans Pharma reported revenue of Rs 841 Cr, operating profit of Rs 213 Cr, an operating margin of 25.33%, and net profit of Rs 159 Cr.

What is the valuation of Marksans Pharma ahead of Q2 results?

Ans. Marksans Pharma trades at a CMP of Rs 335.50, with a trailing PE of 29.36x on an EPS of Rs 11.43, a price to book ratio of 5.03x, and a return on equity of 15.2%, against a market capitalisation of around Rs 15,187 crore.